Ute Stroher

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. ncbi request reprint Blockage of filoviral glycoprotein processing by use of a protein-based inhibitor
    Ute Stroher
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Manitoba, Canada R3E 3R2
    J Infect Dis 196:S271-5. 2007
  2. ncbi request reprint Progress towards the treatment of Ebola haemorrhagic fever
    Ute Stroher
    National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, R3E3R2, Canada
    Expert Opin Investig Drugs 15:1523-35. 2006
  3. ncbi request reprint In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics
    Allison Groseth
    National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 196:S382-9. 2007
  4. ncbi request reprint Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
  5. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
  6. ncbi request reprint Ebola virus ecology: a continuing mystery
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Trends Microbiol 12:433-7. 2004
  7. ncbi request reprint Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha
    Ute Stroher
    National Microbiology Laboratory, Health Canada, and Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    J Infect Dis 189:1164-7. 2004
  8. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
  9. ncbi request reprint Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
  10. pmc Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses
    Michael Garbutt
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba, Canada R3E 3R2
    J Virol 78:5458-65. 2004

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Blockage of filoviral glycoprotein processing by use of a protein-based inhibitor
    Ute Stroher
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Manitoba, Canada R3E 3R2
    J Infect Dis 196:S271-5. 2007
    ..Thus, furin inhibitors are unlikely to be effective in the treatment of filoviral infections...
  2. ncbi request reprint Progress towards the treatment of Ebola haemorrhagic fever
    Ute Stroher
    National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, R3E3R2, Canada
    Expert Opin Investig Drugs 15:1523-35. 2006
    ..The current development in this field encourages discussions on how to move some of the experimental approaches towards clinical application...
  3. ncbi request reprint In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics
    Allison Groseth
    National Laboratory for Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 196:S382-9. 2007
    ..Therefore, we explored the application of minigenomes as screening tools to identify functional siRNA targets under biosafety level 2 conditions...
  4. ncbi request reprint Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
    ..In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus expressing the Zaire ebolavirus (ZEBOV) glycoprotein...
  5. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
    ....
  6. ncbi request reprint Ebola virus ecology: a continuing mystery
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Trends Microbiol 12:433-7. 2004
  7. ncbi request reprint Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha
    Ute Stroher
    National Microbiology Laboratory, Health Canada, and Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    J Infect Dis 189:1164-7. 2004
    ..In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN- alpha might be justified to determine a beneficial effect on the outcome of SARS...
  8. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    ..Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates...
  9. ncbi request reprint Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
    ..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model...
  10. pmc Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses
    Michael Garbutt
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba, Canada R3E 3R2
    J Virol 78:5458-65. 2004
    ..Our data suggest that the recombinant VSV can be used to study the role of the viral glycoproteins in virus replication, immune response, and pathogenesis...
  11. pmc The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola
    Allen Grolla
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 5:e1183. 2011
    ..Marburg virus (MARV), a zoonotic pathogen causing severe hemorrhagic fever in man, has emerged in Angola resulting in the largest outbreak of Marburg hemorrhagic fever (MHF) with the highest case fatality rate to date...
  12. doi request reprint Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011
    ..All 8 MAb improved survival rates by 33%-100% against a high dose lethal challenge with mouse-adapted ZEBOV. This work has important implications for further development of vaccines and immunotherapies for ZEBOV infection...
  13. pmc Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function
    Victoria M Wahl-Jensen
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba
    J Virol 79:10442-50. 2005
    ..Furthermore, sGP, the major soluble glycoprotein of Ebola virus, seems to possess an anti-inflammatory role by protecting the endothelial cell barrier function...
  14. pmc Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages
    Victoria Wahl-Jensen
    Special Pathogens Program, National Microbiology Laboratory, University of Manitoba, Winnipeg, Manitoba, Canada
    J Virol 79:2413-9. 2005
    ..The secreted glycoproteins do not appear to play any role in exogenous activation of these cells during Ebola virus infection...
  15. pmc Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model
    Dennis A Bente
    Special Pathogens Program, National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    J Virol 84:11089-100. 2010
    ..This new mouse model exhibits key features of fatal human CCHF, proves useful for the testing of therapeutic strategies, and can be used to study virus attenuation...
  16. ncbi request reprint Molecular characterization of an isolate from the 1989/90 epizootic of Ebola virus Reston among macaques imported into the United States
    Allison Groseth
    Special Pathogens Program, Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
    Virus Res 87:155-63. 2002
    ..The sequence determination provides the basis for the development of a reverse genetics system for Ebola virus Reston, which is needed to study differences in pathogenicity among filoviruses...